Should I buy or sell Aptose Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks .

What is Aptose Biosciences' stock price target for 2024?

5 analysts have issued 1-year price objectives for Aptose Biosciences' stock. Their APTO share price targets range from $5.00 to $38.00. On average, they anticipate the company's share price to reach $19.80 in the next twelve months. This suggests a possible upside of 1,471.4% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts .

How have APTO shares performed in 2024?

Aptose Biosciences' stock was trading at $2.54 at the beginning of the year. Since then, APTO stock has decreased by 50.4% and is now trading at $1.26. View the best growth stocks for 2024 here .

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 70.5% from the March 15th total of 50,200 shares. Based on an average daily volume of 96,300 shares, the short-interest ratio is currently 0.9 days. Currently, 0.9% of the company's stock are short sold. View Aptose Biosciences' Short Interest .

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our APTO earnings forecast .

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share for the quarter, meeting the consensus estimate of ($1.65). During the same period last year, the firm earned ($4.05) EPS.

When did Aptose Biosciences' stock split?

Shares of Aptose Biosciences reverse split on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com . William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH) , Arch Therapeutics (ARTH) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Anavex Life Sciences (AVXL) , CymaBay Therapeutics (CBAY) , Cisco Systems (CSCO) , Micron Technology (MU) and SCYNEXIS (SCYX) .

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free APTO Stock Alerts

$1.26

-0.01 (-0.79%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.26
▼
$1.34
50-Day Range: $1.26
▼
$2.07
52-Week Range: $1.20
▼
$8.70

Volume: 31,324 shs
Average Volume: 90,711 shs
Market Capitalization: $19.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.80

Get Aptose Biosciences alerts:

Aptose Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,471.4% Upside
$19.80 Price Target
Short Interest: Healthy
0.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.31) to ($3.11) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

Medical Sector

637th out of 914 stocks

Biological Products, Except Diagnostic Industry

98th out of 138 stocks

3.5

Analyst's Opinion

Consensus Rating
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aptose Biosciences has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.92% of the float of Aptose Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Aptose Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptose Biosciences has recently increased by 70.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aptose Biosciences does not currently pay a dividend.
Dividend Growth
Aptose Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APTO.

1.4

News and Social Media Coverage

News Sentiment
Aptose Biosciences has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aptose Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
8 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.53% of the stock of Aptose Biosciences is held by insiders.
Percentage Held by Institutions
Only 26.62% of the stock of Aptose Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aptose Biosciences are expected to grow in the coming year, from ($3.31) to ($3.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptose Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptose Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Aptose Biosciences Stock (NASDAQ:APTO)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APTO Stock News Headlines

April 17, 2024 | americanbankingnews.com

Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from Analysts

March 29, 2024 | investing.com

Aptose Biosciences target cut, maintains buy rating on new drug development

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023

March 27, 2024 | finance.yahoo.com

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript

March 27, 2024 | msn.com

Edgewood secures $20m in Series A for clinical development of cancer therapy

March 27, 2024 | benzinga.com

Recap: Aptose Biosciences Q4 Earnings

March 26, 2024 | globenewswire.com

Aptose Reports Results for the Fourth Quarter and Full Year 2023

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 18, 2024 | globenewswire.com

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

January 29, 2024 | finance.yahoo.com

This Aptose Biosciences Insider Increased Their Holding In The Last Year

January 26, 2024 | marketwatch.com

Aptose Biosciences Shares Drop 11% After Private, Public Offerings

January 26, 2024 | markets.businessinsider.com

Aptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With Hanmi

January 26, 2024 | finance.yahoo.com

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

January 26, 2024 | investorplace.com

Why Is Aptose Biosciences (APTO) Stock Down Today?

December 21, 2023 | benzinga.com

Aptose Biosciences Stock (NASDAQ:APTO), Guidance and Forecast

December 5, 2023 | morningstar.com

Aptose Biosciences Inc APTO

December 4, 2023 | msn.com

Aptose Biosciences files to sell ordinary shares, warrants

December 1, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

November 12, 2023 | seekingalpha.com

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

November 11, 2023 | benzinga.com

Aptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning Calls

November 10, 2023 | benzinga.com

Aptose Biosciences: Q3 Earnings Insights

November 10, 2023 | markets.businessinsider.com

Promising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph Pantginis

November 9, 2023 | msn.com

Aptose Biosciences GAAP EPS of -$1.76 beats by $0.22

November 1, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)

November 1, 2023 | markets.businessinsider.com

Promising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy Rating

October 30, 2023 | finance.yahoo.com

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

See More Headlines

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/23/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:APTO
CUSIP: N/A
CIK: 882361
Web: www.aptose.com
Phone: 858-926-2730
Fax: 905-234-2120
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.80
High Stock Price Target: $38.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,471.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.7189)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -458.70%
Return on Assets: -205.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.78
Quick Ratio: 0.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.19) per share
Price / Book: -6.63

Miscellaneous

Outstanding Shares: 15,720,000
Free Float: 14,220,000
Market Cap: $19.81 million
Optionable: No Data
Beta: 1.29

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO
Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer
Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations
Dr. Stephen B. Howell (Age 73)
Chief Medical Officer
Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price target for 2024?: 5 analysts have issued 1-year price objectives for Aptose Biosciences' stock. Their APTO share price targets range from $5.00 to $38.00. On average, they anticipate the company's share price to reach $19.80 in the next twelve months. This suggests a possible upside of 1,471.4% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.
How have APTO shares performed in 2024?: Aptose Biosciences' stock was trading at $2.54 at the beginning of the year. Since then, APTO stock has decreased by 50.4% and is now trading at $1.26.
View the best growth stocks for 2024 here.
Are investors shorting Aptose Biosciences?: Aptose Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 70.5% from the March 15th total of 50,200 shares. Based on an average daily volume of 96,300 shares, the short-interest ratio is currently 0.9 days. Currently, 0.9% of the company's stock are short sold.
View Aptose Biosciences' Short Interest.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our APTO earnings forecast.
How were Aptose Biosciences' earnings last quarter?: Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share for the quarter, meeting the consensus estimate of ($1.65). During the same period last year, the firm earned ($4.05) EPS.

When did Aptose Biosciences' stock split?: Shares of Aptose Biosciences reverse split on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?: 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.
What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).
How do I buy shares of Aptose Biosciences?: Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APTO) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aptose Biosciences (APTO) Stock Price, News & Analysis

Aptose Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aptose Biosciences Stock (NASDAQ:APTO)

APTO Stock Price History

APTO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

APTO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™